This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

ARCA biopharma Dividends and Buybacks

Dividend criteria checks 0/6

ARCA biopharma does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-0.03%

Buyback Yield

Total Shareholder Yield	-0.03%
Future Dividend Yield	n/a
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

Jul 15

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

Mar 30

Enrollment underway in ARCA bio's mid-stage AB201 study in COVID-19

Dec 15

We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth

Dec 15

ARCA Biopharma wins FDA Fast Track status for experimental COVID treatment

Nov 24

ARCA biopharma reports Q3 results

Nov 02

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ABIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ABIO's dividend payments have been increasing.

Dividend Yield vs Market

ARCA biopharma Dividend Yield vs Market

How does ABIO dividend yield compare to the market?
Segment	Dividend Yield
Company (ABIO)	n/a
Market Bottom 25% (US)	1.4%
Market Top 25% (US)	4.2%
Industry Average (Biotechs)	2.3%
Analyst forecast (ABIO) (up to 3 years)	n/a

Notable Dividend: Unable to evaluate ABIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ABIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ABIO's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ABIO has not reported any payouts.

This company is no longer active

ARCA biopharma Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

Oruka Therapeutics entered into a definitive agreement to acquire ARCA biopharma, Inc. (NasdaqCM:ABIO) for approximately $180 million in a reverse merger transaction.

Companies Like ARCA biopharma (NASDAQ:ABIO) Can Afford To Invest In Growth

Oruka Therapeutics entered into a definitive agreement to acquire ARCA biopharma, Inc. (NasdaqCM:ABIO) in a reverse merger transaction.

New major risk - Share price stability

Arca Biopharma, Inc. Announces Executive Changes

ARCA biopharma, Inc., Annual General Meeting, Jan 30, 2024

ARCA biopharma, Inc. Announces Departure of Christopher D. Ozeroff as Senior Vice President and General Counsel

ARCA biopharma, Inc. Appoints James Flynn to Board of Directors

Insufficient new directors

ARCA biopharma, Inc., Annual General Meeting, Dec 15, 2022

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

ARCA Biopharma, Inc. Appoints Jacob Ma-Weaver Has Joined Its Board of Directors

ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation Play

Insufficient new directors

ARCA biopharma Establishes Special Committee of the Board of Directors

ARCA biopharma, Inc. Announces Results for ASPEN-COVID-19 Phase 2b Clinical Trial

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

ARCA biopharma, Inc. Announces Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2

ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

Senior VP recently bought US$113k worth of stock

ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

ARCA biopharma, Inc. Provides Update on Aspen-Covid-19 Phase 2B Clinical Trial

Chief Accounting Officer & VP of Finance has left the company

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

New 90-day low: US$3.98

New 90-day high: US$4.93

New 90-day high: US$4.55

ARCA biopharma, Inc. Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19

Enrollment underway in ARCA bio's mid-stage AB201 study in COVID-19

We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth

ARCA biopharma, Inc. Announces AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation

ARCA Biopharma wins FDA Fast Track status for experimental COVID treatment

New 90-day low: US$3.81

ARCA biopharma reports Q3 results

New 90-day low: US$4.03

ARCA biopharma, Inc. Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19

ARCA biopharma, Inc. Announces Promotion of Debra Marshall to Chief Medical Officer

New 90-day low: US$4.18

ARCA biopharma, Inc. Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19

New 90-day low - US$5.34

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies